Compositions and methods for treating bone conditions
A method of treating a degenerative bone condition of a subject includes administering to hematopoietic progenitor cells or osteoclast progenitor cells of the subject at least one agent that substantially reduces the interaction of at least one of C3a or C5a with the C3a receptor (C3aR) and/or C5a receptor (C5aR), a STAT3/IL-6 signaling pathway antagonist, and a combination thereof, the agent being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of hematopoietic progenitor cells or osteoclast progenitor cells.
1. A method of treating a degenerative bone condition in a subject in need thereof, the method comprising:
administering locally to hematopoietic progenitor cells or osteoclast progenitor cells a C3a receptor (C3aR) antagonist directed against C3aR, the C3aR antagonist being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of the hematopoietic progenitor cells or osteoclast progenitor cells, the hematopoietic progenitor cells or osteoclast progenitor cells being in the subject or administered to the subject.
2. The method of claim 1 , wherein the C3aR antagonist is an antibody directed against C3aR.
3. The method of claim 1 , further comprising administering a C5aR antagonist to the hematopoietic progenitor cells or osteoclast progenitor cells, wherein the C5aR antagonist is an antibody directed against C5a receptor (C5aR).
4. The method of claim 1 , the C3aR antagonist being administered locally to the hematopoietic progenitor cells or osteoclast progenitor cells at the site of the bone condition.
5. The method of claim 2 , the C3aR antagonist being conjugated to a targeting moiety that targets hematopoietic progenitor cells or osteoclast progenitor cells.
6. The method of claim 1 wherein the bone condition comprises osteopenia or osteoporosis.
7. A method of treating post-menopausal osteoporosis in a subject in need thereof, the method comprising:
administering locally to hematopoietic progenitor cells or osteoclast progenitor cells a C3a receptor (C3aR) antagonist directed against C3aR, the C3aR antagonist being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of the hematopoietic progenitor cells or osteoclast progenitor cells, the hematopoietic progenitor cells or osteoclast progenitor cells being in the subject or administered to the subject.
8. The method of claim 7 , wherein the C3aR antagonist is an antibody directed against C3aR.
9. The method of claim 7 , further comprising administering a C5aR antagonist to the hematopoietic progenitor cells or osteoclast progenitor cells, wherein the C5aR antagonist is an antibody directed against C5a receptor (C5aR).
10. The method of claim 7 , the C3aR antagonist being administered locally to the hematopoietic progenitor cells or osteoclast progenitor cells of bone marrow of the subject.
11. The method of claim 8 , the antibody being conjugated to a targeting moiety that targets hematopoietic progenitor cells or osteoclast progenitor cells of bone marrow of the subject.
12. A method of treating post-menopausal osteoporosis of a subject, the method comprising:
administering locally to bone marrow of the subject a C3a receptor (C3aR) antagonist directed against C3aR, the C3aR antagonist being administered locally to the bone marrow cells of the subject at an amount effective to inhibit osteoclast differentiation of hematopoietic progenitor cells or osteoclast progenitor cells.
13. The method of claim 12 , wherein the C3aR antagonist is an antibody directed against C3aR.
14. The method of claim 12 , further comprising administering a C5aR antagonist to the bone marrow, the C5aR antagonist is an antibody directed against C5aR.
15. The method of claim 1 , wherein the method further comprises administering a STAT3/IL-6 signaling pathway antagonist to the subject.
16. The method of claim 1 , further comprising administering a C5a receptor (C5aR) antagonist to the hematopoietic progenitor cells or osteoclast progenitor cells.
17. The method of claim 7 , further comprising administering a C5a receptor (C5aR) antagonist to the hematopoietic progenitor cells or osteoclast progenitor cells.
18. The method of claim 12 , further comprising administering a C5a receptor (C5aR) antagonist to the hematopoietic progenitor cells or osteoclast progenitor cells.